Source: ERJ Open Res, 7 (4) 00511-2021; 10.1183/23120541.00511-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Conceptor Kaaba, Maria Ruperez, Barry Kosloff, Nduku Ndunda, Kwame Shanaube, Helen Ayles. Assessing usability of QIAreach QuantiFERON-TB platform in a high tuberculosis prevalence, low-resource setting. ERJ Open Res, 7 (4) 00511-2021; 10.1183/23120541.00511-2021

Member's Comments

No comment yet.

Related content which might interest you: Low real-world utility of IGRA when screening for LTBI in a low incidence setting Source: International Congress 2015 – Screening strategies in TB Year: 2015 Programmatic experience with QuantiFERON-TB gold in-tube assay for contact screening in congregate settings in Singapore Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment Year: 2008 Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Source: Eur Respir J 2012; 40: 161-168 Year: 2012 The prevalence of latent tuberculosis infection in a children social center: Comparison of QuantiFERON-TB Gold with tuberculin skin testing Source: Annual Congress 2010 - Tuberculosis in children Year: 2010 How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Source: Eur Respir J 2015; 45: 549-554 Year: 2015 Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection Source: Eur Respir J 2012; 40: 1443-1449 Year: 2012 Screening healthcare workers for Mycobacterium TB: Is QFT-G now the test of choice? Source: Annual Congress 2012 - Abestosis, silicosis and hypersensitivity pneumonitis Year: 2012 Evaluation of latent tuberculosis infection in health care workers by QuantiFERON-TB Gold test and tuberculin skin test Source: Annual Congress 2011 - Risk assessment for tuberculosis Year: 2011 Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms Source: Eur Respir J 2011; 39: 163-171 Year: 2012 Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms Source: Eur Respir J 2012; 39: 163-171 Year: 2012 IP-10 point-of-care tests for monitoring treatment efficacy in tuberculosis in a low-resource setting Source: International Congress 2017 – Update on TB: latest news Year: 2017 Comparison of the QuantiFERON-TB and tuberculin skin test for detection of latent tuberculosis infection in cancer patients in a developing country Source: ERJ Open Res, 5 (4) 00258-2018; 10.1183/23120541.00258-2018 Year: 2019 IGRA testing to diagnose TB disease and infection. What is new in clinical practice and for programmatic management Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 A comparison of QuantiFERON-TB Gold In-Tube test and new QuantiFERON-Microtube assay in children suspect of active TB and adults with active TB Source: Annual Congress 2011 - Tuberculosis in pregnancy and childhood Year: 2011 Usefulness of a daignostic method of tuberculosis infection, QuantiFERON TB-2G, in a contact investigation of medical staffs Source: Eur Respir J 2006; 28: Suppl. 50, 139s Year: 2006 The effect of the introduction of IGRA in screening French healthcare workers for tuberculosis Source: Annual Congress 2012 - Tuberculosis: epidemiological and public health features Year: 2012 Prevalence of LTBI using IGRA and TST in a cohort of health professional trainees from India Source: Annual Congress 2011 - Risk assessment for tuberculosis Year: 2011 Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India Source: Eur Respir J 2014; 44: 1090-1093 Year: 2014 QuantiFERON-TB® Gold Plus as a potential tuberculosis treatment monitoring tool Source: Eur Respir J , 49 (3) 1601976; DOI: 10.1183/13993003.01976-2016 Year: 2017